[
  {
    "ts": null,
    "headline": "AbbVie makes $380 million 'made in the U.S.' move",
    "summary": "The Chicago-based biopharmaceutical company AbbVie made a significant move on Feb. 23, as part of its broader commitment to invest heavily in U.S. research and development over the next 10 years. AbbVie said it will invest$380 million to expand active pharmaceutical ingredient (API) manufacturing ...",
    "url": "https://finnhub.io/api/news?id=c75f37958cc15a40c76b5b7e3e990a5c86298ee1122e683d5812476d756b491b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771970220,
      "headline": "AbbVie makes $380 million 'made in the U.S.' move",
      "id": 139202388,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "The Chicago-based biopharmaceutical company AbbVie made a significant move on Feb. 23, as part of its broader commitment to invest heavily in U.S. research and development over the next 10 years. AbbVie said it will invest$380 million to expand active pharmaceutical ingredient (API) manufacturing ...",
      "url": "https://finnhub.io/api/news?id=c75f37958cc15a40c76b5b7e3e990a5c86298ee1122e683d5812476d756b491b"
    }
  },
  {
    "ts": null,
    "headline": "How Pipeline Shifts And Competition Are Reshaping The AbbVie (ABBV) Investment Narrative",
    "summary": "AbbVie’s fair value estimate has been updated slightly, moving from about US$244.96 to about US$248.29 per share, which gives you a fresh reference point for where some models place the stock today. Behind that shift, research houses are weighing upbeat views on the pipeline and immunology assets against cautious takes on execution risk and competition, which is feeding into more fine tuned targets rather than sweeping calls. As you read on, you will see how these adjustments fit into the...",
    "url": "https://finnhub.io/api/news?id=537ca619daaaad420aa5f629e6823470ba90b9fc49f78cce8ee825d546c64e6b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771960286,
      "headline": "How Pipeline Shifts And Competition Are Reshaping The AbbVie (ABBV) Investment Narrative",
      "id": 139200875,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie’s fair value estimate has been updated slightly, moving from about US$244.96 to about US$248.29 per share, which gives you a fresh reference point for where some models place the stock today. Behind that shift, research houses are weighing upbeat views on the pipeline and immunology assets against cautious takes on execution risk and competition, which is feeding into more fine tuned targets rather than sweeping calls. As you read on, you will see how these adjustments fit into the...",
      "url": "https://finnhub.io/api/news?id=537ca619daaaad420aa5f629e6823470ba90b9fc49f78cce8ee825d546c64e6b"
    }
  },
  {
    "ts": null,
    "headline": "OTC Artificial Tears Market Competitive Landscape Report 2025: Key Players Analysis, Profiles, Strategic Developments, Mergers, Product Innovations, Revenue Insights, and Future Forecasts to 2033",
    "summary": "The OTC Artificial Tears market is projected to expand from USD 4.93 billion in 2025 to USD 7.22 billion by 2033, growing at a CAGR of 4.88%. This growth is driven by increased accessibility in public spaces, rising dry eye syndrome cases due to aging and digital exposure, and heightened awareness of eye health. Artificial tears mimic natural tears to relieve dry eyes, making them integral to eye care routines. Key players, including AbbVie, Akorn, Alcon, Bausch Health, and Johnson & Johnson, ar",
    "url": "https://finnhub.io/api/news?id=8b985a8f59c2f1e5b402b5e6f08cb5d8775c91271d2d8191c4236b0adfd43628",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771949700,
      "headline": "OTC Artificial Tears Market Competitive Landscape Report 2025: Key Players Analysis, Profiles, Strategic Developments, Mergers, Product Innovations, Revenue Insights, and Future Forecasts to 2033",
      "id": 139198791,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "The OTC Artificial Tears market is projected to expand from USD 4.93 billion in 2025 to USD 7.22 billion by 2033, growing at a CAGR of 4.88%. This growth is driven by increased accessibility in public spaces, rising dry eye syndrome cases due to aging and digital exposure, and heightened awareness of eye health. Artificial tears mimic natural tears to relieve dry eyes, making them integral to eye care routines. Key players, including AbbVie, Akorn, Alcon, Bausch Health, and Johnson & Johnson, ar",
      "url": "https://finnhub.io/api/news?id=8b985a8f59c2f1e5b402b5e6f08cb5d8775c91271d2d8191c4236b0adfd43628"
    }
  },
  {
    "ts": null,
    "headline": "Is AbbVie Stock Underperforming the Dow?",
    "summary": "Although AbbVie has lagged behind the Dow recently, analysts remain moderately optimistic about the stock’s prospects.",
    "url": "https://finnhub.io/api/news?id=9358d30765b2ccc2384ab68d3ab3598a65dd45007e5859578e42531782765181",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771946980,
      "headline": "Is AbbVie Stock Underperforming the Dow?",
      "id": 139200876,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Although AbbVie has lagged behind the Dow recently, analysts remain moderately optimistic about the stock’s prospects.",
      "url": "https://finnhub.io/api/news?id=9358d30765b2ccc2384ab68d3ab3598a65dd45007e5859578e42531782765181"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It",
    "summary": "Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.",
    "url": "https://finnhub.io/api/news?id=f1fa31d685721af75e1973c6f5177d72323e322e818254544f0b5c70050b6689",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771941609,
      "headline": "AbbVie Inc. (ABBV) Is a Trending Stock: Facts to Know Before Betting on It",
      "id": 139197303,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.",
      "url": "https://finnhub.io/api/news?id=f1fa31d685721af75e1973c6f5177d72323e322e818254544f0b5c70050b6689"
    }
  },
  {
    "ts": null,
    "headline": "MoonLake: Downgrade To Buy As Sonelokimab Still Has A BLA Shot On Goal",
    "summary": "MoonLake: Downgrade To Buy As Sonelokimab Still Has A BLA Shot On Goal",
    "url": "https://finnhub.io/api/news?id=96be40d5268f9b8e59031cf300e9e46c0da0004e252dc659344a52e5fade5827",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771941012,
      "headline": "MoonLake: Downgrade To Buy As Sonelokimab Still Has A BLA Shot On Goal",
      "id": 139199577,
      "image": "",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=96be40d5268f9b8e59031cf300e9e46c0da0004e252dc659344a52e5fade5827"
    }
  },
  {
    "ts": null,
    "headline": "This High‑Yield Pharma Beast AbbVie Could Turn Dividends Into Life‑Changing Income",
    "summary": "AbbVie's dividend yield is far above the market's, and the dividend has been growing for years.",
    "url": "https://finnhub.io/api/news?id=4fefbf54a5d74dc0a8aa65209c3758e3f48b28490bcd9e534967f5d60d8d4b3f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771939200,
      "headline": "This High‑Yield Pharma Beast AbbVie Could Turn Dividends Into Life‑Changing Income",
      "id": 139194318,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie's dividend yield is far above the market's, and the dividend has been growing for years.",
      "url": "https://finnhub.io/api/news?id=4fefbf54a5d74dc0a8aa65209c3758e3f48b28490bcd9e534967f5d60d8d4b3f"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie to Present at the TD Cowen 46th Annual Health Care Conference",
    "summary": "AbbVie (NYSE: ABBV) will participate in the TD Cowen 46th Annual Health Care Conference on Tuesday, March 3, 2026. Management will participate in a fireside chat at 10:10 a.m. Central Time.",
    "url": "https://finnhub.io/api/news?id=7587c895f3dc2445ebcb53fb4331196b437b151d9ab39bf6d7dff4bf099a0cb3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771938000,
      "headline": "AbbVie to Present at the TD Cowen 46th Annual Health Care Conference",
      "id": 139194375,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie (NYSE: ABBV) will participate in the TD Cowen 46th Annual Health Care Conference on Tuesday, March 3, 2026. Management will participate in a fireside chat at 10:10 a.m. Central Time.",
      "url": "https://finnhub.io/api/news?id=7587c895f3dc2445ebcb53fb4331196b437b151d9ab39bf6d7dff4bf099a0cb3"
    }
  },
  {
    "ts": null,
    "headline": "Hormone Replacement Therapy Market Competitive Landscape Report 2025: Top Players Analysis, Profiles, Strategic Developments, Mergers, Product Innovations and Launches, Sustainability Goals, Revenues",
    "summary": "The Hormone Replacement Therapy (HRT) market is poised to expand significantly from $23.58 billion in 2025 to $38.18 billion by 2033, driven by a CAGR of 6.21%. Key growth drivers include technological advancements, innovations in delivery methods, and rising cases of hormonal disorders. Increased awareness and acceptance of HRT, largely for menopause-related symptoms in women, alongside supportive government policies, further contribute to market growth. The sector sees immense potential, parti",
    "url": "https://finnhub.io/api/news?id=eb43ff69c7c22b310521cf4bc951ee0003642e39641dad783bf7e02ae9847d41",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771934460,
      "headline": "Hormone Replacement Therapy Market Competitive Landscape Report 2025: Top Players Analysis, Profiles, Strategic Developments, Mergers, Product Innovations and Launches, Sustainability Goals, Revenues",
      "id": 139194419,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "The Hormone Replacement Therapy (HRT) market is poised to expand significantly from $23.58 billion in 2025 to $38.18 billion by 2033, driven by a CAGR of 6.21%. Key growth drivers include technological advancements, innovations in delivery methods, and rising cases of hormonal disorders. Increased awareness and acceptance of HRT, largely for menopause-related symptoms in women, alongside supportive government policies, further contribute to market growth. The sector sees immense potential, parti",
      "url": "https://finnhub.io/api/news?id=eb43ff69c7c22b310521cf4bc951ee0003642e39641dad783bf7e02ae9847d41"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie to spend $380M on two 2 manufacturing facilities in Illinois",
    "summary": "The active pharmaceutical ingredient manufacturing facilities are part of a broader $100 billion investment commitment to strengthen the company’s U.S. manufacturing capabilities.",
    "url": "https://finnhub.io/api/news?id=23f4b047023a773c7dedabdb3d124e36594984d2a1b5d6ef9e5ffbf6642bfdb9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771930898,
      "headline": "AbbVie to spend $380M on two 2 manufacturing facilities in Illinois",
      "id": 139198807,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "The active pharmaceutical ingredient manufacturing facilities are part of a broader $100 billion investment commitment to strengthen the company’s U.S. manufacturing capabilities.",
      "url": "https://finnhub.io/api/news?id=23f4b047023a773c7dedabdb3d124e36594984d2a1b5d6ef9e5ffbf6642bfdb9"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie announces $380m investment in North Chicago API facilities",
    "summary": "Construction is scheduled to commence in spring 2026, with both facilities anticipated to be fully operational by 2029.",
    "url": "https://finnhub.io/api/news?id=da2f60e061972789e0dc10766dfdd10ebd5afdb4b6fdb059a7238df32a9b479b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771922886,
      "headline": "AbbVie announces $380m investment in North Chicago API facilities",
      "id": 139192438,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Construction is scheduled to commence in spring 2026, with both facilities anticipated to be fully operational by 2029.",
      "url": "https://finnhub.io/api/news?id=da2f60e061972789e0dc10766dfdd10ebd5afdb4b6fdb059a7238df32a9b479b"
    }
  },
  {
    "ts": null,
    "headline": "FDA Approves AbbVie (ABBV) VENCLEXTA and Acalabrutinib Combination for First-Line CLL",
    "summary": "AbbVie Inc. (NYSE:ABBV) is one of the best value stocks to buy now. On February 20, the US FDA approved the combination of VENCLEXTA (venetoclax) and acalabrutinib as a first-line treatment for adults with chronic lymphocytic leukemia/CLL. This establishes the first and only all-oral, fixed-duration regimen for previously untreated patients, providing a new alternative to […]",
    "url": "https://finnhub.io/api/news?id=3238b31d0b7c4b03425cff56f273b6932710cf6d6e68494a22b50ac70e2ff0b4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771917068,
      "headline": "FDA Approves AbbVie (ABBV) VENCLEXTA and Acalabrutinib Combination for First-Line CLL",
      "id": 139191716,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie Inc. (NYSE:ABBV) is one of the best value stocks to buy now. On February 20, the US FDA approved the combination of VENCLEXTA (venetoclax) and acalabrutinib as a first-line treatment for adults with chronic lymphocytic leukemia/CLL. This establishes the first and only all-oral, fixed-duration regimen for previously untreated patients, providing a new alternative to […]",
      "url": "https://finnhub.io/api/news?id=3238b31d0b7c4b03425cff56f273b6932710cf6d6e68494a22b50ac70e2ff0b4"
    }
  }
]